People | March 07, 2023
Aptar appoints Julie Xing to its Board of Directors
Julie is recognized as a highly engaging multi-cultural leader skilled in fluidly partnering with cross-functional teams to deliver results.
Julie is recognized as a highly engaging multi-cultural leader skilled in fluidly partnering with cross-functional teams to deliver results.
The collaboration will focus on developing a localized and sustained-release drug delivery system for oncology patients
Julian Collins, Jana Windt and Michiel Stork join biopharma company’s leadership team
New workflow integrates the xCELLigence RTCA HT with the BioTek BioSpa 8 Automated Incubator
Designation based on positive data from Phase 2b KEYNOTE-942/mRNA-4157-P201 trial
This action follows the recent acceptance of the Marketing Authorization Application (MAA) for Pfizer’s RSV vaccine candidate by the European Medicines Agency
New subgroup analysis from Phase III ARASENS trial shows that darolutamide plus androgen deprivation therapy (ADT) in combination with docetaxel increased overall survival (OS)
Astellas stands on the forefront of healthcare change to turn innovative science into value for patients
Data build on previously reported results from the primary endpoint of investigator-assessed radiographic progression-free survival
FDA also accepts a separate supplemental application to extend prophylaxis with PREVYMIS to 200 days in certain HSCT recipients
Subscribe To Our Newsletter & Stay Updated
